Termination agreement ending the Biocon Agreements; technical service fee owed to us set off against amounts we owed Biocon
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Bruce D. Steel
Also a director
Chief Executive Officer
|
59 | Not stated | Not stated | $4,255,248 | |
|
Christine Zedelmayer
Chief Operating Officer
|
56 |
Since 2020
6 years
|
2018 | $2,102,076 | |
|
Daniel M. Bradbury
Also a director
CHAIRMAN
Title from the Form 4 dated May 28, 2026
|
64 | Not stated | Not stated | Not reported | |
|
Stephen Connelly
President and CSO
Title from the Form 4 dated Jun 4, 2026
|
44 | Not stated | Not stated | $2,701,826 | |
|
Penny Tom
Principal Accounting Officer
Title from the Form 4 dated May 28, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Termination agreement ending the Biocon Agreements; technical service fee owed to us set off against amounts we owed Biocon
Co-funding of a Phase 2 clinical study of itolizumab in ulcerative colitis conducted by Biocon in India; our share of study costs
Work order with Syngene for chemistry, manufacturing and controls services for itolizumab, substantially all paused in Q3 2024
Acquisition of Ariagen under a stock purchase agreement; we assumed Ariagen liabilities and may owe regulatory approval milestones, up to $50.6 million of which would go to Decheng affiliates
Loading...